- Home
- VIVS vs CPHI Comparison
VIVS vs CPHI Comparison
Compare VIVS & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- CPHI
- Stock Information
- Founded
- VIVS 2007
- CPHI N/A
- Country
- VIVS United States
- CPHI China
- Employees
- VIVS N/A
- CPHI N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- CPHI Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- CPHI Health Care
- Exchange
- VIVS Nasdaq
- CPHI Nasdaq
- Market Cap
- VIVS 4.6M
- CPHI 5.3M
- IPO Year
- VIVS N/A
- CPHI N/A
- Fundamental
- Price
- VIVS $1.77
- CPHI $1.43
- Analyst Decision
- VIVS
- CPHI
- Analyst Count
- VIVS 0
- CPHI 0
- Target Price
- VIVS N/A
- CPHI N/A
- AVG Volume (30 Days)
- VIVS 53.7K
- CPHI 90.2K
- Earning Date
- VIVS 08-12-2025
- CPHI 08-26-2025
- Dividend Yield
- VIVS N/A
- CPHI N/A
- EPS Growth
- VIVS N/A
- CPHI N/A
- EPS
- VIVS N/A
- CPHI N/A
- Revenue
- VIVS $142,000.00
- CPHI $4,396,201.00
- Revenue This Year
- VIVS $42.38
- CPHI N/A
- Revenue Next Year
- VIVS $15.42
- CPHI N/A
- P/E Ratio
- VIVS N/A
- CPHI N/A
- Revenue Growth
- VIVS 94.52
- CPHI N/A
- 52 Week Low
- VIVS $1.41
- CPHI $1.20
- 52 Week High
- VIVS $21.96
- CPHI $3.35
- Technical
- Relative Strength Index (RSI)
- VIVS N/A
- CPHI 36.67
- Support Level
- VIVS N/A
- CPHI $1.29
- Resistance Level
- VIVS N/A
- CPHI $1.52
- Average True Range (ATR)
- VIVS 0.00
- CPHI 0.13
- MACD
- VIVS 0.00
- CPHI -0.02
- Stochastic Oscillator
- VIVS 0.00
- CPHI 22.22
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.